Literature DB >> 17035054

Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening.

Mutasem O Taha1, Yasser Bustanji, Amal G Al-Bakri, Al-Motassem Yousef, Waleed A Zalloum, Ihab M Al-Masri, Naji Atallah.   

Abstract

A pharmacophoric model was developed for human protein tyrosine phosphatase 1B (h-PTP 1B) inhibitors utilizing the HipHop-REFINE module of CATALYST software. Subsequently, genetic algorithm and multiple linear regression analysis were employed to select an optimal combination of physicochemical descriptors and pharmacophore hypothesis that yield consistent QSAR equation of good predictive potential (r = 0.87,F-statistic = 69.13,r(BS)2 = 0.76,r(LOO)2 = 0.68). The validity of the QSAR equation and the associated pharmacophoric hypothesis was experimentally established by the identification of five new h-PTP 1B inhibitors retrieved from the National Cancer Institute (NCI) database.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17035054     DOI: 10.1016/j.jmgm.2006.08.008

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  14 in total

1.  Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors.

Authors:  Rand Shahin; Saja Alqtaishat; Mutasem O Taha
Journal:  J Comput Aided Mol Des       Date:  2011-12-14       Impact factor: 3.686

Review 2.  Structure--activity relationships of polymyxin antibiotics.

Authors:  Tony Velkov; Philip E Thompson; Roger L Nation; Jian Li
Journal:  J Med Chem       Date:  2010-03-11       Impact factor: 7.446

3.  Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.

Authors:  Mahmoud A Al-Sha'er; Mohammad A Khanfar; Mutasem O Taha
Journal:  J Mol Model       Date:  2014-01-28       Impact factor: 1.810

4.  The use of docking-based comparative intermolecular contacts analysis to identify optimal docking conditions within glucokinase and to discover of new GK activators.

Authors:  Mutasem O Taha; Maha Habash; Mohammad A Khanfar
Journal:  J Comput Aided Mol Des       Date:  2014-03-08       Impact factor: 3.686

5.  Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors.

Authors:  Sawsan Abuhamdah; Maha Habash; Mutasem O Taha
Journal:  J Comput Aided Mol Des       Date:  2013-12-12       Impact factor: 3.686

6.  Application of docking-based comparative intermolecular contacts analysis to validate Hsp90α docking studies and subsequent in silico screening for inhibitors.

Authors:  Mahmoud A Al-Sha'er; Mutasem O Taha
Journal:  J Mol Model       Date:  2012-06-16       Impact factor: 1.810

7.  Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets.

Authors:  Rand Shahin; Lubna Swellmeen; Omar Shaheen; Nour Aboalhaija; Maha Habash
Journal:  J Comput Aided Mol Des       Date:  2015-12-19       Impact factor: 3.686

8.  Discovery of new β-D-glucosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening.

Authors:  Reema Abu Khalaf; Ahmed Mutanabbi Abdula; Mohammad S Mubarak; Mutasem O Taha
Journal:  J Mol Model       Date:  2010-05-21       Impact factor: 1.810

9.  Combining molecular dynamics simulation and ligand-receptor contacts analysis as a new approach for pharmacophore modeling: beta-secretase 1 and check point kinase 1 as case studies.

Authors:  Ma'mon M Hatmal; Shadi Jaber; Mutasem O Taha
Journal:  J Comput Aided Mol Des       Date:  2016-10-08       Impact factor: 3.686

10.  Discovery of potent inhibitors for phosphodiesterase 5 by virtual screening and pharmacophore analysis.

Authors:  Chien-yu Chen; Yea-huey Chang; Da-tian Bau; Hung-jin Huang; Fuu-jen Tsai; Chang-hai Tsai; Calvin Yu-chian Chen
Journal:  Acta Pharmacol Sin       Date:  2009-07-13       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.